HDAC inhibitors: a 2013-2017 patent survey

FARIA FREITAS, Micaela, CUENDET LICEA, Muriel, BERTRAND, Philippe. HDAC inhibitors: a 2013-2017 patent survey. In: Expert Opinion on Therapeutic Patents, 2018, p. 1–17. doi: 10.1080/13543776.2018.1459568

Article (Published version)

Identifiers

PID : unige:121508
DOI : 10.1080/13543776.2018.1459568
PMID : 29671355

ISSN of the journal1354-3776

215views

0downloads

Creation2019/07/09 11:58:00

First validation2019/07/09 11:58:00

Update time2023/03/15 17:50:29

Status update2023/03/15 17:50:29

Last indexation2024/05/05 15:10:06

Archive ouverte UNIGE

HDAC inhibitors: a 2013-2017 patent survey

Zinc-dependent histone deacetylases (HDAC) inhibitors represent an important class of biologically active compounds with four of them approved by the FDA. A wide range of molecules has been reported for applications in several human diseases.

Technical informations